tiprankstipranks
Trending News
More News >
0RA9 Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings0RA9 Upcoming Earnings Report: What to Expect?
1M ago
Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity
Premium
Ratings
Optimistic Buy Rating for Abivax SA: Obefazimod’s Potential in Ulcerative Colitis and Market Opportunity
2M ago
Promising Potential of Abivax SA’s Obefazimod in Ulcerative Colitis Drives Buy Rating
Premium
Ratings
Promising Potential of Abivax SA’s Obefazimod in Ulcerative Colitis Drives Buy Rating
2M ago
Abivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating
PremiumRatingsAbivax SA: Promising Clinical Developments and Positive Outlook Justify Buy Rating
3M ago
Abivax Files Key Financial Documents with Regulatory Authorities
Premium
Company Announcements
Abivax Files Key Financial Documents with Regulatory Authorities
3M ago
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength
Premium
Ratings
Promising Prospects for Abivax: Buy Rating Backed by Clinical Progress and Financial Strength
3M ago
Abivax assumed with an Equal Weight at Morgan Stanley
PremiumThe FlyAbivax assumed with an Equal Weight at Morgan Stanley
4M ago
Buy Rating for Abivax SA Driven by Promising Obefazimod Data and Market Potential
Premium
Ratings
Buy Rating for Abivax SA Driven by Promising Obefazimod Data and Market Potential
4M ago
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025
Premium
Ratings
Abivax’s Obefazimod: A Promising New Treatment for Ulcerative Colitis with Phase 3 Data Anticipated in 2025
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100